Gazette.govt.nzPursuant to section 20 of the Medicines Act 1981, the Minister of Health hereby consents to the distribution in New Zealand of the new medicines which were referred to the Minister of Health under the provisions of section 24(5) of the Act and are set out in the Schedule hereto:
Schedule
| Product: | Imfinzi |
| Active Ingredient: | Durvalumab 120mg |
| Dosage Form: | Concentrate for infusion |
| New Zealand Sponsor: | AstraZeneca Limited |
| Manufacturers: | Catalent Indiana LLC, Indiana, United States of America Vetter Pharma-Fertigung GmbH & Co KG, Ravensburg, Germany |
| Product: | Imfinzi |
| Active Ingredient: | Durvalumab 500mg |
| Dosage Form: | Concentrate for infusion |
| New Zealand Sponsor: | AstraZeneca Limited |
| Manufacturers: | Catalent Indiana LLC, Indiana, United States of America Vetter Pharma-Fertigung GmbH & Co KG, Ravensburg, Germany |
| Product: | Penthrox |
| Active Ingredient: | Methoxyflurane 99.9%w/w |
| Dosage Form: | Volatile liquid for inhalation |
| New Zealand Sponsor: | Douglas Pharmaceuticals Limited |
| Manufacturer: | Medical Developments International Limited, Melbourne, Australia |
| Product: | Vicks Vaporub |
| Active Ingredients: | Eucalyptus oil 1.33%w/w Menthol 2.82%w/w |
| Dosage Form: | Topical ointment |
| New Zealand Sponsor: | CARSL Consulting |
| Manufacturer: | Makson Health Care (Private) Limited, Annaram, India |
Dated this 17th day of September 2021.
CHRIS JAMES, Group Manager, Medsafe, Ministry of Health (pursuant to delegation given by the Minister of Health on 11 September 2013).